baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

GRIFOLS SA INH. A EO-,25/ ES0171996087 /

08/10/2024 18:44:11	Chg. -0.110	Volume	Bid18:52:18	Ask18:52:18	Market Capitalization	Dividend Y.	P/E Ratio
10.095EUR	-1.08%	284 Turnover: 2,875.500	10.015Bid Size: 696	10.110Ask Size: 696	8.55 bill.EUR	-	112.00

GlobeNewswire 29/07 Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strength...

TeleTrader 08/07 Grifols family, Brookfield consider €5.5B takeover bid for Grifols

GlobeNewswire 01/07 Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

GlobeNewswire 18/06 Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

GlobeNewswire 17/06 Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immu...

GlobeNewswire 18/04 Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at ...

GlobeNewswire 04/04 Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Scree...

GlobeNewswire 14/02 Grifols announces positive topline phase 3 fibrinogen clinical trial results

TeleTrader 09/01 Grifols tumbles as much as 40% on fraud allegations

GlobeNewswire 15/11/2023 Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous ...

GlobeNewswire 24/10/2023 Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s V...

TeleTrader 28/07/2020 Grifols says its anti-COVID-19 therapeutics ready for trials

GRIFOLS SA INH. A EO-,25/ ES0171996087 /

If you wish to receive reply to your feedback, please provide your email address.